A possible route to depleting leukemic stem cells while preserving healthy hematopoietic stem cells has opened up, with the discovery that cyclin-dependent kinase regulatory subunit 1 inhibition suppresses cancer stem cells and at the same time protects healthy stem cells from the toxic effects of chemotherapy.

Investigators at Stanford University and Baylor College of Medicine have identified an exercise-induced appetite suppressant that led to weight loss when administered to obese mice. The molecule, Lac-Phe, has led to predictable excitement around the possibility of appetite-suppressing exercise in a pill.

Failure to ovulate and release mature oocytes is one of the most common female infertility problems. With increasing age or conditions like obesity, no oocytes are released even on ovulation induction with hormonal treatment.

Researchers at Hannover Medical School have gained new insights into the cytokine meteorin-like (METRNL) and its role in promoting heart repair after myocardial infarction.

It is well known that the development of a new drug is exorbitantly expensive and is a process which usually fails. Researchers at PrecisionLife posit that failure and the many patients with unmet treatment needs result from an over simplistic view of disease pathogeneses and an overreliance on a narrow range of target genes and pathways.

The eyes may be the window to the heart as well as the soul – particularly, to whether that heart is at risk of an infarct, researchers reported last week at the annual congress of the European Society of Human Genetics.

New treatments for cardiac hypertrophy, a thickening of the heart in response to pressure overload, could potentially treat or even reverse the condition after a new breakthrough discovery identified the mechanism that causes the heart's muscle to thicken, increasing the risk of irregular heart rhythms and heart failure.

At the European Hematology Association's annual meeting in Vienna last week, companies reported impressive progress for the treatment of sickle cell disease.

At the European Hematology Association’s annual meeting in Vienna last week, companies reported impressive progress for the treatment of sickle cell disease.

At the 2022 Annual Congress of the European Hematology Association, researchers from the Spanish National Cancer Institute reported how high levels of the RNA-binding protein hnRNP-K could lead to bone marrow failure.